Biotech RadarJobs updated

COMPANY

Tempest Therapeutics

HQ: Brisbane, CA source · tempesttx.com ↗ · West Coast

Clinical Phase 3

Keywords: CAR-T oncology immunology Colorectal Cancer Non Small Cell Lung Cancer Squamous Cell Carcinoma of Head and Neck Urothelial Carcinoma Endometrial Cancer Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma Solid Tumors With PIK3Ca Mutation Hepatocellular Carcinoma Metastatic Castration Resistant Prostate Cancer Renal Cell Carcinoma Triple-Negative Breast Cancer Cholangiocarcinoma GastroEsophageal Cancer Pancreatic Cancer Sarcoma TPST-1495 TPST-1120

Location: Brisbane, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$12.8MRaised (2 yrs)3Trials (company is sponsor)

Timeline

  1. Partnership Partnership / licensing announced Sep 15, 2026. Source: SEC filing. source ↗
  2. Raise Private placement: $2.5M (total, as published), announced Sep 11, 2026. Source: company release on GlobeNewswire. source ↗ · Form D filed Oct 14, 2026 SEC Form D ↗
  3. Partnership Partnership / licensing announced Jul 21, 2026. Source: SEC filing. source ↗
  4. Raise Private placement: $2M (total, as published), announced Mar 23, 2026. Source: company release on GlobeNewswire. source ↗ · Form D filed Apr 3, 2026 SEC Form D ↗
  5. Trial start Phase 3: A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy source ↗
  6. Raise Follow-on offering — Registered direct: $8.35M (up to, as announced), announced Nov 25, 2025. Source: SEC filing. source ↗
  7. Trial start 1: Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors source ↗
  8. Trial start Phase 1: TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $12.8M. Last 2 years.

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT04344795Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors1CompletedMay 6, 2020Sep 25, 2024 (actual)
NCT06680258A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic TherapyPhase 3Not yet recruiting2025-122028-12 (estimated)
NCT03829436TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersPhase 1CompletedMar 20, 2019Sep 7, 2022 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback